Page 1

GRIFOLS Free translation from the original in Spanish . In the event of discrepancy , the Spanish language version will prevail . First Quarter 2021 Results • • • • Grifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply Grifols reports EUR 1,185 million in revenues , an operational¹ decline of 0.9 % . Contributions from new products and price increases on specific plasma proteins partially offset lower sales volumes due to COVID - 19 impacted lower plasma collections , bringing Bioscience Division revenues to EUR 901 million , an operational decline of 5.6 % . The Diagnostic and Hospital Divisions report solid sales revenues of EUR 203 million ( 28.0 % cc ) and EUR 31 million ( 4.3 % cc ) , respectively . Bio Supplies Commercial continues to grow by double digits . EBITDA totals EUR 322 million , excluding the impact of exchange rate variations . EBITDA margins at 25.1 % . Grifols ' gross margin stands at 45.0 % . Grifols continues to strengthen its innovation strategy : Alkahest and GigaGen place Grifols on the leading edge of bioscience , while diversifying and reinforcing its R + D + i pipeline . Grifols accelerates the execution of its expansion plan to immediately access an additional 1.4 million liters of plasma per year , while moving forward with the opening of new centers . Barcelona , May 4 , 2021.- Grifols ( MCE : GRF , MCE : GRF.P , NASDAQ : GRFS ) reported EUR 1,184.7 million in revenues in the first quarter of 2021 , a decline of 0.9 % cc and 8.4 % taking into account exchange rate variations . The company maintained its operational levels in the first quarter despite these unprecedented times , limiting COVID - 19 - related impacts through contributions from new products , continuous efforts to increase plasma donations , effective inventory management , and the expansion of Grifols ' plasma collection capacity . ¹Operative or constant currency ( cc ) excludes exchange rate variations reported in the period . Page 1 of 12